Austin, Texas - May 1, 2023 - Pattern Bioscience, a biotechnology research company developing cutting-edge diagnostic technology to combat the global threat of antimicrobial resistance, announced today the closing of a $28.7 million Series C funding round led by Illumina Ventures, with participation from existing investors.

Co-founded by Nicolas Arab, Pattern Bioscience is dedicated to developing the world's only culture-free, rapid diagnostic technology for bacterial infections that will reduce pathogen identification (ID) and antibiotic susceptibility test (AST) results from days to hours. The company's innovative technology combines single-cell analysis of microorganisms with machine learning tools to deliver fast, clinically actionable information.

Each year, drug-resistant bacterial infections claim more than a million lives globally, and the healthcare industry incurs billions of dollars in costs. Traditional diagnostic methods for bacterial infections are slow, cumbersome, and rely on decades-old technology that often leads to sub-optimal treatment and the misuse of broad-spectrum antibiotics.

The new funding will be used to further advance Pattern Bioscience's groundbreaking technology and accelerate its commercialization efforts. With the support of Illumina Ventures and other investors, Pattern Bioscience is poised to revolutionize the way bacterial infections are diagnosed and treated.